TG Therapeutics, Inc. (NASDAQ:TGTX) Stock Position Raised by Castleark Management LLC

Castleark Management LLC increased its stake in TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) by 25.2% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 211,370 shares of the biopharmaceutical company's stock after purchasing an additional 42,560 shares during the period. Castleark Management LLC owned 0.14% of TG Therapeutics worth $6,362,000 at the end of the most recent reporting period.

Several other hedge funds have also made changes to their positions in TGTX. Bleakley Financial Group LLC acquired a new stake in TG Therapeutics in the 4th quarter valued at approximately $245,000. Castellan Group acquired a new stake in TG Therapeutics in the 4th quarter valued at approximately $8,539,000. Barclays PLC increased its position in TG Therapeutics by 83.9% in the 3rd quarter. Barclays PLC now owns 347,057 shares of the biopharmaceutical company's stock valued at $8,117,000 after acquiring an additional 158,323 shares during the period. Stratos Wealth Advisors LLC acquired a new stake in TG Therapeutics in the 4th quarter valued at approximately $241,000. Finally, Strategic Financial Concepts LLC acquired a new stake in TG Therapeutics in the 4th quarter valued at approximately $1,404,000. Institutional investors own 58.58% of the company's stock.

Analysts Set New Price Targets

Several research firms recently commented on TGTX. Wall Street Zen upgraded TG Therapeutics from a "sell" rating to a "hold" rating in a research report on Tuesday, March 4th. HC Wainwright restated a "buy" rating and issued a $55.00 target price on shares of TG Therapeutics in a research report on Tuesday, March 4th. Two equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. According to data from MarketBeat.com, TG Therapeutics currently has a consensus rating of "Moderate Buy" and an average target price of $40.80.

TG Therapeutics Price Performance

Shares of TGTX stock traded up $0.33 during mid-day trading on Friday, hitting $34.57. 1,042,767 shares of the stock traded hands, compared to its average volume of 2,983,166. TG Therapeutics, Inc. has a twelve month low of $15.16 and a twelve month high of $46.48. The firm has a market cap of $5.49 billion, a price-to-earnings ratio of -345.67 and a beta of 2.21. The company's 50-day simple moving average is $38.13 and its 200-day simple moving average is $34.22. The company has a debt-to-equity ratio of 1.27, a quick ratio of 3.91 and a current ratio of 4.59.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last issued its quarterly earnings results on Wednesday, May 7th. The biopharmaceutical company reported $0.03 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.19 by ($0.16). TG Therapeutics had a negative net margin of 5.42% and a negative return on equity of 8.32%. The firm had revenue of $120.86 million for the quarter, compared to analyst estimates of $117.07 million. During the same quarter last year, the business posted ($0.07) earnings per share. The firm's revenue for the quarter was up 90.4% compared to the same quarter last year. As a group, equities research analysts expect that TG Therapeutics, Inc. will post 0.08 earnings per share for the current year.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.